The influence of long-term awareness of hyperlipidemia and of 3 years of dietary counseling on depression, anxiety, and quality of life☆☆☆
Received 8 October 2008; received in revised form 3 November 2009; accepted 3 November 2009. published online 16 December 2009.
Abstract
Objective
The purpose of this study is to investigate the long-term effects of participation in a cardiovascular screening program and of dietary counseling on self-reported psychosocial outcomes and health concerns.
Methods
High-risk subjects (n=563) with hyperlipidemia from the Oslo Diet and Antismoking Study (1972–1977) were reexamined after 25 years and randomly assigned to a new 3-year prospective 2×2 factorial placebo-controlled study in 1997 of n-3 polyunsaturated fatty acids and/or dietary counseling.
Hospital Anxiety and Depression Scale (HADS), Life Satisfaction Index (LSI), and a new questionnaire on health concerns and behavior in response to risk information were collected at the 25-year follow-up. Hospital Anxiety and Depression Scale and LSI were evaluated at the end of the 3-year Diet and Omega-3 Intervention Trial on atherosclerosis (DOIT) in 505 subjects.
Results
Twenty-five years after the screening program, HADS-anxiety was similar to the Norwegian norms (3.3 vs. 3.5), while HADS-depression was significantly lower (3.6 vs. 4.1, P<.01). Patients reported that 25 years of awareness of hyperlipidemia had influenced health concerns through a moderate change in diet habits, some restriction in life conduct, but an improvement of the total life situation.
After a novel 3-year intervention in DOIT, there was no difference between the dietary counseling and control group with regard to anxiety, depression, or life satisfaction, but HADS-anxiety increased significantly (4.0 vs. 3.3, P<.001) in both groups.
Conclusion
Compared to the general population, screening-positive subjects did not have increased mental distress 25 years after screening, and beneficial health behavior persisted. Dietary counseling did not affect psychosocial outcomes.
This article is dedicated to the memory of Ingrid Ellingsen, who passed away after this paper was finished.
☆ The study was conducted at Oslo University Hospital Ulleval, Oslo, Norway.
☆☆ DOIT received financial support from the Norwegian Cardiovascular Council and the Norwegian retail company RIMI. n-3 PUFA and placebo capsules were provided by LUBA DK. Mills DA provided vegetable oil and VITA margarine. There are no reported conflicts of interests.